Therapeutic inhibitor of vascular smooth muscle cells

Details Therapeutic inhibitor of vascular smooth muscle cells Therapeutic inhibitor of vascular smooth muscle cells

A - Human Necessities

61

K

A61K 31/135 (2006.01) A61K 31/138 (2006.01) A61K 31/337 (2006.01) A61K 31/40 (2006.01) A61K 31/4025 (2006.01) A61K 31/4035 (2006.01) A61K 31/407 (2006.01) A61K 47/48 (2006.01)

Patent

CA 2162587

Sustained release dosage forms of TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are characterized by a reduced vessel lumen diameter. In a preferred embodiment of the invention, TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. Free TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose may be used in conjunction with the sustained release dosage forms described herein for prophylactic purposes with respect to disease and trauma states involving proliferation and/or migration of vascular smooth muscle cells over time.

Affiliated with

Also associated with

Rating

Therapeutic inhibitor of vascular smooth muscle cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic inhibitor of vascular smooth muscle cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic inhibitor of vascular smooth muscle cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1357661